Cargando…

A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum‐Sensitive Ovarian Cancer

PURPOSE: The noninterventional, prospective NIMES‐ROC phase IV study (NCT02825420) evaluated trabectedin plus pegylated liposomal doxorubicin (PLD) in real‐life clinical practice. PATIENTS AND METHODS: Eligible participants included adults with platinum‐sensitive recurrent ovarian cancer (PS‐ROC) wh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pignata, Sandro, Scambia, Giovanni, Villanucci, Alessandro, Naglieri, Emanuele, Ibarbia, Mikel Arruti, Brusa, Federica, Bourgeois, Hugues, Sorio, Roberto, Casado, Antonio, Reichert, Dietmar, Dopchie, Catherine, De Rivas, Beatriz, de Sande, Luis Miguel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Gynecologic Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018301/ https://www.ncbi.nlm.nih.gov/pubmed/33289956 http://dx.doi.org/10.1002/onco.13630

Ejemplares similares

Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study
por: Runnebaum, Ingo B., et al.
Publicado: (2018)

Trabectedin plus Pegylated Liposomal Doxorubicin: Retrospective Analysis in Heavily Pretreated Platinum-sensitive Ovarian Cancer
por: Nicoletto, Maria Ornella, et al.
Publicado: (2015)

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval
por: Kaye, S. B., et al.
Publicado: (2011)

Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer
por: Rubio Pérez, María Jesús
Publicado: (2017)

Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer
por: Jones, Robin L., et al.
Publicado: (2021)

Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells
por: Marczak, Agnieszka, et al.
Publicado: (2014)

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial
por: Poveda, A., et al.
Publicado: (2011)

A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer
por: Takahashi, Shunji, et al.
Publicado: (2021)

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial
por: Pignata, Sandro, et al.
Publicado: (2006)

Real-life experience using trabectedin plus pegylated liposomal doxorubicin combination to treat patients with relapsed ovarian cancer
por: Tahir, Saad
Publicado: (2014)

Pegylated liposomal doxorubicin in the management of ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2010)

Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
por: Guerra Alía, Eva María, et al.
Publicado: (2019)

Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial
por: Wang, Tiantian, et al.
Publicado: (2022)

Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain
por: Ojeda, B, et al.
Publicado: (2003)

Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer
por: Pisano, Carmela, et al.
Publicado: (2013)

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
por: Colmegna, B, et al.
Publicado: (2015)

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
por: Colombo, N., et al.
Publicado: (2023)

Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer
por: López-Guerrero, José Antonio, et al.
Publicado: (2015)

PEGylated liposomes: immunological responses
por: Mohamed, Marwa, et al.
Publicado: (2019)

Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006)

Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009)

Pegylated liposomal doxorubicin for myeloid neoplasms
por: Zhang, Cheng, et al.
Publicado: (2019)

Evidence of Protein Adsorption in Pegylated Liposomes: Influence of Liposomal Decoration
por: Sangrà, Marc, et al.
Publicado: (2017)

Prognostic values of DNA mismatch repair genes in ovarian cancer patients treated with platinum-based chemotherapy
por: Zhao, Chuchu, et al.
Publicado: (2017)

Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
por: Kavanagh, John J, et al.
Publicado: (2010)

Adipose tissue area is a predictive biomarker for the efficacy of pegylated liposomal doxorubicin in platinum‐refractory/resistant ovarian cancer
por: Yoshida, Hiroyuki, et al.
Publicado: (2023)

Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer(,,)
por: Kim, Kenneth H., et al.
Publicado: (2015)

A tale of the two PEGylated liposomal doxorubicins
por: Chou, Hunghsueh, et al.
Publicado: (2015)

Interactions of primaquine and chloroquine with PEGylated phosphatidylcholine liposomes
por: Miatmoko, Andang, et al.
Publicado: (2021)

Conventional and PEGylated Liposomes as Vehicles of Copaifera sabulicola
por: Blanco, Ian M. R., et al.
Publicado: (2023)

Femur metastasis in carcinoma of the uterine cervix: a rare entity
por: Corrado, Giacomo, et al.
Publicado: (2009)

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence
por: Mascilini, Floriana, et al.
Publicado: (2014)

Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)
por: Hamanishi, Junzo, et al.
Publicado: (2021)

Pegylated Liposomal Doxorubicin-induced Palmar-plantar Erythrodysesthesia
por: Moreira-Barros, Joana, et al.
Publicado: (2018)

Prolonged use of pegylated liposomal doxorubicin in gynecologic malignancies
por: Yost, S., et al.
Publicado: (2019)

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
por: Yuan, Zhen, et al.
Publicado: (2021)

Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma
por: Ghaferi, Mohsen, et al.
Publicado: (2022)

The Impact of Nanobody Density on the Targeting Efficiency of PEGylated Liposomes
por: Mesquita, Bárbara S., et al.
Publicado: (2022)

Diagnostic factors for recurrent pregnancy loss: an expanded workup
por: Ticconi, Carlo, et al.
Publicado: (2023)

The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: A low-value intervention?
por: Cohn, David E., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ri5r8nfjdbgvcntlofj5srct7a